A Phase 3 interventional study of Paliperidone extended release (ER) and Aripiprazole in Schizophrenia, sponsored by Janssen Research & Development, LLC. Completed at 44 sites in 7 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2013-06-21.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 47th largest by enrollment, is one of 11 that started in 2009, is one of 41 in phase 3, and was the 50th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 11 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 228 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 68th largest by enrollment of the 176 interventional ones that give a count, is one of 13 that started in 2009, is one of 74 in phase 3, and was the 126th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of extended-release (ER) paliperidone compared to aripiprazole (atypical antipsychotic) in symptomatic (having symptoms) adolescent participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations [imagining things], and withdrawal into the self) .
This is a multi-center (conducted in more than 1 center), double-blind (neither physician nor participant knows the name of the assigned drug), randomized (study drug is assigned by chance), active-controlled (paliperidone ER is compared to aripiprazole), parallel-group (a medical research study comparing the response in 2 or more groups of participants receiving different treatments), flexible-dose (the physician has the freedom to give different doses to the participant depending on how they respond to treatment) study designed to determine the efficacy and safety of paliperidone ER in symptomatic adolescents (12 to 17 years of age) with schizophrenia. The total duration of the study will be approximately 29 weeks. The study consists of 3 phases: a Screening phase up to 3 weeks (with a possible overlapping washout period), a Double-blind acute phase of 8 weeks, and a Double-blind maintenance phase of 18 weeks. Participants will be randomly assigned to 1 of the 2 treatment groups (paliperidone ER or aripiprazole flexible oral doses). Dosage will be adjusted at the scheduled visits. Efficacy of the participants will primarily be evaluated through Positive and Negative Syndromes Scale (PANSS). Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paliperidone ER will be administered as oral capsule at a dose of 6 milligram (mg) for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
Drug: Paliperidone extended release (ER)
Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
Drug: Aripiprazole
Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56
The PANSS is a 30-item scale with each item rated on a scale of 1 (absent) to 7 (extreme psychopathology), designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Baseline and Day 56
Change From Baseline in PANSS Total Score at Day 182
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Baseline and Day 182
Change From Baseline in Marder Factor Negative Symptoms Score at Day 56 and 182
The PANSS negative subscale based on marder factor assesses 7 negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).
Time frame: Baseline, Day 56 and Day 182
Change From Baseline in Other Marder Factors Scores at Day 56 and 182
The subscales based on marder factors are: positive symptoms, disorganised thoughts factor, uncontrolled hostility/excitement factor, and anxiety/depression factor. The symptoms are rated on a 7-point scale, with a range of 8 to 56 for positive symptoms, 7 to 49 for disorganized thoughts and 4 to 28 for Uncontrolled hostility/excitement and anxiety/depression. Higher score indicate worsening.
Time frame: Baseline, Day 56 and 182
Change From Baseline in Other PANSS Factors and Subscales at Day 56 and 182
The PANSS provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a scale of 1 (absent) to 7 (extreme).
Time frame: Baseline, Day 56 and 182
Number of Participants With Clinical Stability
Clinical stability is defined as a decrease of 20 percent or more from Baseline in PANSS total score and CGI-S score less than or equal to 4 at Days 56 and 182, no hospitalizations due to psychiatric illness and no emergence of clinically significant suicidal or homicidal ideation during the maintenance phase.
Time frame: Day 56 and 182
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Days 56 and 182
The CGI-S rating scale is a 7-point global assessment that measures the Clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.
Time frame: Baseline, Day 56 and 182
Change From Baseline in Personal and Social Performance (PSP) Scores at Day 56 and 182
The PSP scale assesses degree of a participants' dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The results of the assessment are converted to a numerical score to rate degree of difficulty (1=absent to 6=very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score (total score ranges from 1 to 100, divided into 10 equal intervals). Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.
Time frame: Baseline, Day 56 and Day 182
Number of Participants With PANSS Response
The PANSS is a 30-item scale with each item rated on a scale of 1 (absent) to 7 (extreme psychopathology), designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Participants with PANSS response were defined as those who achieved greater than or equal to 20 percent or higher reduction from Baseline in the PANSS total score at Day 56 and 182.
Time frame: Day 56 and 182
| Milestone | Paliperidone Extended Release (ER) | Aripiprazole |
|---|---|---|
| Started | 113 | 115 |
| Completed | 85 | 89 |
| Not completed | 28 | 26 |
| Withdrew: Adverse event | 5 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Lack of efficacy | 4 | 11 |
| Withdrew: Withdrawal by consent | 16 | 11 |
| Withdrew: Other | 3 | 2 |
The PANSS is a 30-item scale with each item rated on a scale of 1 (absent) to 7 (extreme psychopathology), designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Paliperidone Extended Release (ER) | Aripiprazole |
|---|---|---|
| Baseline | 89.6 ± 12.22 | 92.0 ± 12.09 |
| Change at Day 56 | -19.3 ± 13.80 | -19.8 ± 14.56 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Paliperidone Extended Release (ER) | Aripiprazole |
|---|---|---|
| Baseline | 89.6 ± 12.22 | 92.0 ± 12.09 |
| Change at Day 182 | -25.6 ± 16.88 | -26.8 ± 18.82 |
The PANSS negative subscale based on marder factor assesses 7 negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).
| Units on a scale | Paliperidone Extended Release (ER) | Aripiprazole |
|---|---|---|
| Baseline | 23.2 ± 4.92 | 23.3 ± 4.54 |
| Change at Day 56 | -4.3 ± 4.56 | -4.7 ± 4.61 |
| Change at Day 182 | -6.0 ± 5.51 | -6.2 ± 5.84 |
The subscales based on marder factors are: positive symptoms, disorganised thoughts factor, uncontrolled hostility/excitement factor, and anxiety/depression factor. The symptoms are rated on a 7-point scale, with a range of 8 to 56 for positive symptoms, 7 to 49 for disorganized thoughts and 4 to 28 for Uncontrolled hostility/excitement and anxiety/depression. Higher score indicate worsening.
| Units on a scale | Paliperidone Extended Release (ER) | Aripiprazole |
|---|---|---|
| Baseline: Positive symptoms | 24.6 ± 4.08 | 24.9 ± 4.32 |
| Change at Day 56: Positive symptoms | -6.1 ± 4.96 | -5.6 ± 4.83 |
| Change at Day 182: Positive symptoms | -7.8 ± 5.82 | -7.8 ± 6.03 |
| Baseline: Negative symptoms | 23.2 ± 4.92 | 23.3 ± 4.54 |
| Change at Day 56: Negative symptoms | -4.3 ± 4.56 | -4.7 ± 4.61 |
| Change at Day 182: Negative symptoms | -6.0 ± 5.51 | -6.2 ± 5.84 |
| Baseline: Disorganized thoughts | 21.4 ± 4.40 | 22.1 ± 3.86 |
| Change at Day 56: Disorganized thoughts | -4.0 ± 3.34 | -4.1 ± 3.40 |
| Change at Day 182: Disorganized thoughts | -5.5 ± 4.18 | -5.7 ± 4.46 |
| Baseline: Uncontrolled hostility | 10.7 ± 3.19 | 11.7 ± 3.48 |
| Change at Day 56: Uncontrolled hostility | -2.5 ± 2.67 | -2.9 ± 3.05 |
| Change at Day 182: Uncontrolled hostility | -3.2 ± 3.11 | -3.8 ± 3.97 |
| Baseline: Anxiety/depression | 9.7 ± 3.17 | 10.0 ± 3.26 |
| Change at Day 56: Anxiety/depression | -2.4 ± 3.08 | -2.6 ± 2.81 |
| Change at Day 182: Anxiety/depression | -3.0 ± 3.29 | -3.2 ± 3.17 |
The PANSS provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a scale of 1 (absent) to 7 (extreme).
| Units on a scale | Paliperidone Extended Release (ER) | Aripiprazole |
|---|---|---|
| Baseline: Positive Subscale | 21.5 ± 4.14 | 22.5 ± 4.26 |
| Change at Day 56: Positive Subscale | -6.4 ± 4.54 | -6.2 ± 4.91 |
| Change at Day 182: Positive Subscale | -8.0 ± 5.16 | -8.3 ± 6.09 |
| Baseline: Negative Subscale | 23.8 ± 4.55 | 24.2 ± 4.32 |
| Change at Day 56: Negative Subscale | -4.2 ± 4.25 | 4.5 ± 4.25 |
| Change at Day 182: Negative Subscale | -5.7 ± 5.15 | -6.1 ± 5.47 |
| Baseline: General Psychopathology | 44.3 ± 7.47 | 45.3 ± 7.01 |
| Change at Day 56: General Psychopathology | -8.7 ± 7.35 | -9.1 ± 7.25 |
| Change at Day 182: General Psychopathology | -11.9 ± 9.02 | -12.4 ± 9.41 |
Clinical stability is defined as a decrease of 20 percent or more from Baseline in PANSS total score and CGI-S score less than or equal to 4 at Days 56 and 182, no hospitalizations due to psychiatric illness and no emergence of clinically significant suicidal or homicidal ideation during the maintenance phase.
| Participants | Paliperidone Extended Release (ER) | Aripiprazole |
|---|---|---|
| Number of Participants With Clinical Stability | 58 | 68 |
The CGI-S rating scale is a 7-point global assessment that measures the Clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.
| Units on a scale | Paliperidone Extended Release (ER) | Aripiprazole |
|---|---|---|
| Baseline | 4.0 (3 to 6) | 4.0 (3 to 6) |
| Change at Day 56 | -1.0 (-4 to 0) | -1 (-3 to 1) |
| Change at Day 182 | -1.0 (-4 to 1) | -1.0 (-4 to 1) |
The PSP scale assesses degree of a participants' dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The results of the assessment are converted to a numerical score to rate degree of difficulty (1=absent to 6=very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score (total score ranges from 1 to 100, divided into 10 equal intervals). Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.
| Units on a Scale | Paliperidone Extended Release (ER) | Aripiprazole |
|---|---|---|
| Baseline | 49.8 ± 10.32 | 49.2 ± 10.21 |
| Change at Day 56 | 12.2 ± 11.72 | 12.2 ± 10.17 |
| Change at Day 182 | 17.1 ± 14.46 | 17.1 ± 14.03 |
The PANSS is a 30-item scale with each item rated on a scale of 1 (absent) to 7 (extreme psychopathology), designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Participants with PANSS response were defined as those who achieved greater than or equal to 20 percent or higher reduction from Baseline in the PANSS total score at Day 56 and 182.
| Participants | Paliperidone Extended Release (ER) | Aripiprazole |
|---|---|---|
| Day 56 | 76 | 87 |
| Day 182 | 86 | 93 |
Collected over Baseline up to Week 26. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paliperidone Extended Release (ER) | — | 7/113 (6.2%) | 63/113 (55.8%) |
| Aripiprazole | — | 7/114 (6.1%) | 50/114 (43.9%) |
| Event | Paliperidone Extended Release (ER) | Aripiprazole |
|---|---|---|
| SchizophreniaPsychiatric disorders | 1/113 | 4/114 |
| AgitationPsychiatric disorders | 1/113 | 1/114 |
| AnxietyPsychiatric disorders | 1/113 | 0/114 |
| Schizophrenia, paranoid typePsychiatric disorders | 1/113 | 0/114 |
| Suicide attemptPsychiatric disorders | 1/113 | 0/114 |
| SinusitisInfections and infestations | 1/113 | 0/114 |
| Psychotic disorderPsychiatric disorders | 1/113 | 1/114 |
| Upper respiratory infectionInfections and infestations | 0/113 | 1/114 |
| Event | Paliperidone Extended Release (ER) | Aripiprazole |
|---|---|---|
| AkathisiaNervous system disorders | 13/113 | 9/114 |
| HeadacheNervous system disorders | 12/113 | 5/114 |
| SomnolenceNervous system disorders | 12/113 | 12/114 |
| TremorNervous system disorders | 12/113 | 11/114 |
| Weight increasedInvestigations | 12/113 | 7/114 |
| SchizophreniaPsychiatric disorders | 3/113 | 10/114 |
| InsomniaPsychiatric disorders | 6/113 | 9/114 |
| VomitingGastrointestinal disorders | 8/113 | 1/114 |
| Muscle rigidityMusculoskeletal and connective tissue disorders | 7/113 | 3/114 |
| NauseaGastrointestinal disorders | 4/113 | 7/114 |
| Age Continuous(Years) | Paliperidone Extended Release (ER) | Aripiprazole | Total |
|---|---|---|---|
| Mean | 15.3 ± 1.46 | 15.4 ± 1.45 | 15.3 ± 1.46 |
| Sex: Female, Male(Participants) | Paliperidone Extended Release (ER) | Aripiprazole | Total |
|---|---|---|---|
| Female | 39 | 38 | 77 |
| Male | 73 | 76 | 149 |
The record gives a start of Dec 2009, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone
Janssen Research & Development, LLC →